drugset
drugset / Trial / NCT06586242

Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy

NCT06586242 ↗

Phase 2 Recruiting 194 enrolled Xijing Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.

Timeline

Start
2023-04-03
Primary completion
2025-04
Completion
2036-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobaplatin Small molecule 50 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous
Background Catequentinib Small molecule 8 mg Oral
Background Catequentinib Small molecule 10 mg Oral
Background Paclitaxel Small molecule 260 mg/m2 Intravenous
Background Penpulimab Monoclonal antibody 200 mg Intravenous

Indications

esophageal cancer